Navigation Links
Bayer HealthCare Pharmaceuticals Initiates Phase III Trial with Florbetaben PET Tracer for Imaging of Cerebral beta-Amyloid Plaques, a Pathological Hallmark of Alzheimer's Disease
Date:11/30/2009

iland in October 2009.

About Bayer HealthCare Pharmaceuticals Inc.

Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals business of Bayer HealthCare LLC, a subsidiary of Bayer AG. Bayer HealthCare is one of the world's leading, innovative companies in the healthcare and medical products industry, and combines the activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions. Bayer HealthCare Pharmaceuticals comprises the following business units: Women's Healthcare, Diagnostic Imaging, General Medicine, which includes Cardiology and Primary Care and Specialty Medicine, which includes Hematology, Oncology and Multiple Sclerosis. The company's aim is to discover and manufacture products that will improve human health worldwide by diagnosing, preventing and treating diseases.

This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

SOURCE Bayer HealthCare Pharmaceuticals


'/>"/>
SOURCE Bayer HealthCare Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
2. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
3. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
4. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
5. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
6. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
7. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
8. Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
9. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
10. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
11. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... -- Xencor Inc. (NASDAQ: XNCR ), ... for the treatment of autoimmune diseases, asthma and ... for the second quarter ended June 30, 2014 and ... "In the second quarter, we presented preclinical ... Conference (ATS) demonstrating three novel mechanisms of action ...
(Date:7/31/2014)... , July 31, 2014   Auxilium Pharmaceuticals , ... specialty biopharmaceutical company, today announced that the Company will ... Thursday, August 7, 2014 before the opening of the ... conference call that day at 8:30 a.m. ET to ... 2014. The presentation slides to be used during the ...
(Date:7/31/2014)...  A substantial share of pharmacy and therapeutics ... are included in formularies—say patient support resources from ... Manhattan Research study, Taking the Pulse® Formulary ... P&T committee members in hospitals, managed care organizations ... a high bar for these programs, requiring that ...
Breaking Medicine Technology:Xencor Reports Second Quarter 2014 Financial Results 2Xencor Reports Second Quarter 2014 Financial Results 3Xencor Reports Second Quarter 2014 Financial Results 4Xencor Reports Second Quarter 2014 Financial Results 5Xencor Reports Second Quarter 2014 Financial Results 6Xencor Reports Second Quarter 2014 Financial Results 7Xencor Reports Second Quarter 2014 Financial Results 8Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014 2Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014 3Formulary Decision Makers Say Pharma-Provided Patient Support Solutions Influence Formulary Placement 2Formulary Decision Makers Say Pharma-Provided Patient Support Solutions Influence Formulary Placement 3
... CHICAGO , June 5 Scientists from ... presented preliminary data that shows nitrogen-containing bisphosphonates, therapeutic agents used ... slightly poorer survival rate in post-menopausal women with early stage ... findings were announced today at the 2010 American Society of ...
... BARBARA, Calif. , June 4 Abviva, Inc. (Pink ... of breast cancer related applications of Mammastatin, today provided further details ...   , , , ... appoints W.T. Uniack & Co. as its independent auditor. ...
Cached Medicine Technology:Karmanos Cancer Institute Researchers Study Bisphosphonates and Their Affect on Early Stage Breast Cancer 2Karmanos Cancer Institute Researchers Study Bisphosphonates and Their Affect on Early Stage Breast Cancer 3Karmanos Cancer Institute Researchers Study Bisphosphonates and Their Affect on Early Stage Breast Cancer 4Abviva Engages W.T. Uniack & Co. As Independent Auditor 2
(Date:7/31/2014)... July 31, 2014 In today’s world, a ... to get. Snoring and sleep apnea (a medical problem where ... and their bed partners of the rest they need to ... the population snores and 20 million people in the United ... been diagnosed and treated; and of those treated, many cannot ...
(Date:7/31/2014)... NV (PRWEB) July 31, 2014 Niche Profit ... Adam Short that is designed to provide a blueprint for ... the attention of Shane Michaels, prompting an investigative review. ... , “What really speaks volumes about the success of the ... and strategies included in it have stayed effective even through ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Hook Your Ex, a ... get ex’s to feel emotionally hungry for their partner, to the ... chance. This little trick has been taught to hundreds of ... a quick Hook Your Ex review , Shane Michaels agrees ... suffering pain from a breakup a second chance at getting back ...
(Date:7/31/2014)... CA (PRWEB) July 31, 2014 Cosmetic ... benefit both patients and doctors. Doctors will be able ... to leave reviews , which guarantees their authenticity. ... options on the site to receive information that has ... This unprecedented validation system allows Cosmetic Town to filter ...
(Date:7/31/2014)... Farmington, NY (PRWEB) July 31, 2014 ... restaurants incorporating Pioneer Millworks’ reclaimed wood to create ... the environment. Their newest location features reclaimed ... the restaurant, with custom selected mixed softwoods flowing ... trusses crafted by Pioneer Millworks’ sister company ...
Breaking Medicine News(10 mins):Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Niche Profit Classroom: Review Exposes Adam Short’s Guide to Building Niche Websites 2Health News:Hook Your Ex Review by Shane Michaels Exposes Steve Pratt And His New Method For Getting Back With The Ex 2Health News:Cosmetic Town Improves Patient Experience Through Secure Verification of Patients and Doctors 2Health News:Popular Tavern Restaurant Features Pioneer Millworks’ Reclaimed Wood in New Locations 2
... have raised questions regarding differences in quality of care ... In fact, a growing body of health services research ... the weekend and increased mortality. This "weekend effect" has ... specific intensive treatments and procedures. , Two recent studies ...
... the March 1 issue of the journal SLEEP ... promising model for addressing adolescent sleep problems, given ... healthy sleep knowledge and practice. , The program, ... period, had a high retention rate of 83 percent ...
... green vegetables such as broccoli and cabbage could ... cancer researchers. Tests on mice suggest that these ... safely and effectively than conventional therapy. , "There ... that trigger melanoma," said Gavin Robertson, associate professor ...
... Bethesda, MD (March 1, 2009) Although the ... is well established, studies investigating the association between ... (BE) and esophageal adenocarcinoma (EAC) have reported inconsistent ... of alcohol on BE, especially related to alcohol ...
... Brian Schweitzer, Chair of the Democratic Governors Association, today ... Gov. Kathleen Sebelius as Secretary of Health and Human ... Kathleen Sebelius is an excellent choice to lead the ... our health care system, Governor Sebelius will bring a ...
... precautions should be abandoned, experts note , , SATURDAY, ... trip is as important as packing the right clothes. ... doesn,t mean it,s safe," Laura Gonzalez, a nurse with The ... said in a news release issued by the school. "You ...
Cached Medicine News:Health News:Patients with GI bleeding admitted on the weekend have higher death rate 2Health News:Patients with GI bleeding admitted on the weekend have higher death rate 3Health News:School-based intervention is a promising model for improving adolescent sleep habits 2Health News:School-based intervention is a promising model for improving adolescent sleep habits 3Health News:Vegetable-based drug could inhibit melanoma 2Health News:Alcohol types and socioeconomic status are associated with Barrett's esophagus risk 2Health News:Alcohol types and socioeconomic status are associated with Barrett's esophagus risk 3Health News:Travel Safety Can Be a Passport to Good Health 2
Lyphochek Therapeutic Drug Monitoring Control (TDM) contains over 40 analytes with assayed values at three clinically significant levels....
Lyphochek Endocrine Control is a human based product designed to monitor plasma catecholamine testing procedures by HPLC. The analytes are spiked at critical concentrations to cover the dynamic range...
Lyphochek Urine Metals Control incorporates two levels of critical trace elements, heavy metals and organic metabolites, and is ideal for environmental and industrial testing....
Lyphochek Whole Blood Control is a unique product designed to monitor immunosuppressants, red cell folate and lead in whole blood assays. This control has three critical levels for each analyte and i...
Medicine Products: